%0 Journal Article
%T Alternatives to ketamine in depression: state-of-the-art and future perspectives
%A James M. Stone
%A Luke A. Jelen
%A Sinead King
%J Archive of "Therapeutic Advances in Psychopharmacology".
%D 2018
%R 10.1177/2045125317749456
%X Pharmacological treatments in major depressive disorder (MDD) have historically focused on monoaminergic modulation. However, this strategy has limitations, such as a significant delay in the onset of therapeutic action and a large proportion of patients demonstrating persistent, treatment-resistant depression. There is a real need for novel rapid-acting antidepressants with alternative mechanisms of action
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802640/